Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of plasmodium vivax in rodents

Infection and Immunity

Volumn 82, Issue 2, 2014, Pages 793-807

  Teixeira, Lais H ^a   Tararam, Cibele A ^a   Lasaro, Marcio O ^b,g   Camacho, Ariane G A ^a   Ersching, Jonatan ^a   Leal, Monica T ^a   Herrera, Sócrates ^c   Bruna Romero, Oscar ^d   Soares, Irene S ^e   Nussenzweig, Ruth S ^f   Ertl, Hildegund C J ^b   Nussenzweig, Victor ^f   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b WISTAR INSTITUTE   (United States)

^c Malaria Vaccine and Drug Development Center   (Colombia)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CIRCUMSPOROZOITE PROTEIN; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN G; MALARIA VACCINE; RECOMBINANT PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASES; DRUG EFFICACY; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MALARIA CONTROL; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, VIVAX; MICE; MICE, INBRED C57BL; PLASMODIUM VIVAX; POLY I-C; PROTOZOAN PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84892983927     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01410-13     Document Type: Article

References (58)

1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. 2010. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 6:90-96. http://dx.doi.org/10.4161/hv.6.1.9677.
2. + T cell responses and protection against Plasmodium falciparum infection. PLoS One 8:e61395. http://dx.doi.org/10 .1371/journal.pone.0061395.
3. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kaboré W, Ouédraogo S, Sandrine Y, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Odero C, Oneko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A, Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou WR, Bruls M, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P, RTS,S Clinical Trials Partnership. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365:1863-1875. http: //dx.doi.org/10.1056/NEJMoa1102287.
4. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, RTS,S Clinical Trials Partnership. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284-2295. http://dx.doi.org/10.1056/NEJMoa1208394.
5. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:e774. http://dx.doi.org/10.1371/journal.pntd.0000774.
6. Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V. 1985. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230: 815-818. http://dx.doi.org/10.1126/science.2414847.
7. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, Prasittisuk C. 1989. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science 245:973-976. http://dx.doi.org/10.1126/science.2672336.
8. Qari SH, Shi YP, Povoa MM, Alpers MP, Deloron P, Murphy GS, Harjosuwarno S, Lal AA. 1993. Global occurrence of Plasmodium vivaxlike human malaria parasite. J. Infect. Dis. 168:1485-1489. http://dx.doi.org/10.1093/infdis/168.6.1485.
9. de Arruda M, Souza RC, Veiga ME, Ferreira AF, Zimmerman RH. 1998. Prevalence of Plasmodium vivax variants VK247 and P. vivax-like human malaria: a retrospective study in indigenous Indian populations of the Amazon region of Brazil. Trans. R. Soc. Trop. Med. Hyg. 92:628. http://dx.doi.org/10.1016/S0035-9203(98)90788-X.
10. Marrelli MT, Branquinho MS, Hoffmann EH, Taipe-Lagos CB, Natal D, Kloetzel JK. 1998. Correlation between positive serology for Plasmodium vivax-like/Plasmodium simiovale malaria parasites in the human and anopheline populations in the State of Acre, Brazil. Trans. R. Soc. Trop. Med. Hyg. 92:149 -151. http://dx.doi.org/10.1016/S0035 -9203(98)90723-4.
11. Bonilla JA, Validum L, Cummings R, Palmer CJ. 2006. Genetic diversity of Plasmodium vivax Pvcsp and Pvmsp1 in Guyana, South America. Am. J. Trop. Med. Hyg. 75:830-835. http://www.ajtmh.org/content/75/5/830.full.pdf+html.
12. Gopinath R, Wongsrichanalai C, Cordón-Rosales C, Mirabelli L, Kyle D, Kain KC. 1994. Failure to detect a Plasmodium vivax-like malaria parasite in globally collected blood samples. J. Infect. Dis. 170:1630-1633. http://dx.doi.org/10.1093/infdis/170.6.1630.
13. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451. http://dx.doi.org/10.1016/S1074 -7613(00)80119-3.
14. Leal MT, Ariza Camacho AG, Teixeira LH, Bargieri DY, Soares IS, Tararam CA, Rodrigues MM. 2013. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella Typhimurium flagellin. Clin. Vaccine Immunol. 20:1418-1425. http://dx.doi.org/10.1128/CVI.00312-13.
15. Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, Espíndola NM, Vaz AJ, Soares IS, Ferreira LC, Rodrigues MM. 2008. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26:6132-6142. http://dx.doi.org/10.1016/j.vaccine.2008.08.070.
16. Zhou D, Zhou X, Bian A, Li H, Chen H, Small JC, Li Y, Giles-Davis W, Xiang Z, Ertl HC. 2010. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat. Protoc. 5:1775-1785. http://dx.doi.org/10.1038/nprot.2010.134.
17. Gupta RK, Siber GR. 1995. Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay. J. Immunol. Methods 181:75-81. http://dx.doi.org/10.1016/0022-1759(94)00331-P.
18. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y. 1982. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156:20-30. http://dx.doi.org/10.1084/jem.156.1.20.
19. de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silvério JC, Lannes-Vieira J, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM. 2009. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect. Immun. 77:4383-4395. http://dx.doi.org/10.1128/IAI.01459-08.
20. Vasconcelos JR, Bruña-Romero O, Araújo AF, Dominguez MR, Ersching J, de Alencar BC, Machado AV, Gazzinelli RT, Bortoluci KR, Amarante-Mendes GP, Lopes MF, Rodrigues MM. 2012. Pathogeninduced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8(+) T-cell response: reversal by adenoviral vaccine. PLoS Pathog. 8:e1002699. http://dx.doi.org/10.1371/journal.ppat.1002699.
21. Chattopadhyay R, Velmurugan S, Chakiath C, Andrews Donkor L, Milhous W, Barnwell JW, Collins WE, Hoffman SL. 2010. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One 5:e14275. http://dx.doi.org/10.1371/journal.pone.0014275.
22. Solarte Y, Manzano MR, Rocha L, Hurtado H, James MA, Arévalo-Herrera M, Herrera S. 2011. Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials. Am. J. Trop. Med. Hyg. 84(2 Suppl):28-34. http://dx.doi.org/10.4269/ajtmh.2011.09-0499.
23. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, Duque-Alarcon A, Pan L, Nelkenbaum A, Salazar AM, Schlesinger SJ, Steinman RM, Sékaly RP. 2011. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208:2357-2366. http://dx.doi.org/10.1084/jem.20111171.
24. Clemente T, Dominguez MR, Vieira NJ, Rodrigues MM, Amarante-Mendes GP. 2013. In vivo assessment of specific cytotoxic T lymphocyte killing. Methods 61:105-109. http://dx.doi.org/10.1016/j.ymeth.2013.02.007.
25. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P. 2011. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11:102-109. http://dx.doi.org/10.1016/S1473-3099(10)70262-0.
26. Kebaier C, Voza T, Vanderberg J. 2009. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. PLoS Pathog. 5:e1000399. http://dx.doi.org /10.1371/journal.ppat.1000399.
27. Lacroix C, Ménard R. 2008. TRAP-like protein of Plasmodium sporozoites: linking gliding motility to host-cell traversal. Trends Parasitol. 24: 431-434. http://dx.doi.org/10.1016/j.pt.2008.07.003.
28. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, Corradin G, Persson C, Tewari R, Sinnis P. 2011. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208:341-356. http://dx.doi.org/10.1084/jem.20101488.
29. Montagna GN, Matuschewski K, Buscaglia CA. 2012. Plasmodium sporozoite motility: an update. Front. Biosci. 17:726-744. http://dx.doi.org/10.2741/3954.
30. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71-73. http://dx.doi.org /10.1126/science.6985745.
31. Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F. 2013. Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect. Immun. 81:2882-2887. http://dx.doi.org/10.1128/IAI.00461-13.
32. Arévalo-Herrera M, Soto L, Perlaza BL, Céspedes N, Vera O, Lenis AM, Bonelo A, Corradin G, Herrera S. 2011. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Am. J. Trop. Med. Hyg. 84(2 Suppl):35-42. http://dx.doi.org/10.4269/ajtmh.2011.09-0507.
33. Nardin EH, Nussenzweig RS. 1993. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against preerythrocytic stages. Annu. Rev. Immunol. 11:687-727. http://dx.doi.org /10.1146/annurev.iy.11.040193.003351.
34. Schwenk RJ, Richie TL. 2011. Protective immunity to pre-erythrocytic stage malaria. Trends Parasitol. 27:306-314. http://dx.doi.org/10.1016/j.pt.2011.02.002.
35. Douradinha B, Doolan DL. 2011. Harnessing immune responses against Plasmodium for rational vaccine design. Trends Parasitol. 27:274-283. http://dx.doi.org/10.1016/j.pt.2011.01.002.
36. Sinnis P, Zavala F. 2012. The skin: where malaria infection and the host immune response begin. Semin. Immunopathol. 34:787-792. http://dx.doi.org/10.1007/s00281-012-0345-5.
37. Vaughan AM, Kappe SH. 2012. Malaria vaccine development: persistent challenges. Curr. Opin. Immunol. 24:324-331. http://dx.doi.org/10.1016 /j.coi.2012.03.009.
38. Soares IS, Françoso KS, Jampaulo VO, Rodrigues MM. 2012. CD8(+) T-cell-mediated immunity against malaria: a novel heterologous primeboost strategy. Expert Rev. Vaccines 11:1039-1041. http://dx.doi.org/10.1586/erv.12.82.
39. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. 2006. A DNA primemodified vaccinia virus Ankara boost vaccine encoding thrombospondinrelated adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74:5933-5942. http://dx.doi.org/10.1128/IAI.00590-06.
40. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334:475-480. http://dx.doi.org/10.1126/science.1211548.
41. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Manohar N, Richie NO, Wood C, Long CA, Regis D, Williams FT, Shi M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL. 2011. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 6:e24586. http://dx.doi.org/10.1371/journal.pone.0024586.
42. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL. 2011. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6:e25868. http://dx.doi.org/10.1371/journal.pone.0025868.
43. Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Aguiar JC, Sacci JB, Jr, Sedegah M, Nosek RA, Jr, De La Vega P, Berzins MP, Majam VF, Abot EN, Ganeshan H, Richie NO, Banania JG, Baraceros MF, Geter TG, Mere R, Bebris L, Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, Hobart PM, Norman JA, Soisson LA, Hollingdale MR, Rogers WO, Doolan DL, Hoffman SL. 2012. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/ hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum. Vaccin. Immunother. 8:1564-1584. http://dx.doi.org/10.4161/hv.22129.
44. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL. 2013. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8:e55571. http://dx.doi.org/10.1371/journal.pone.0055571.
45. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341:323-326. http://dx.doi.org/10.1038/341323a0.
46. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, Maryanski JL, Nussenzweig RS, Zavala F. 1991. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 3:579-585. http://dx.doi.org/10.1093 /intimm/3.6.579.
47. Rodrigues M, Nussenzweig RS, Romero P, Zavala F. 1992. The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules. J. Exp. Med. 175:895-905. http://dx.doi.org/10.1084/jem.175.4.895.
48. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, Gilbert SC, Hill AV, Bartholomay LC, Harty JT. 2008. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl. Acad. Sci. U. S. A. 105:14017-14022. http://dx.doi.org/10.1073/pnas.0805452105.
49. Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF. 2007. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect. Immun. 75:1177-1185. http://dx.doi.org/10.1128/IAI.01667-06.
50. Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A. 2011. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect. Immun. 79:3492-3500. http://dx.doi.org/10.1128/IAI.05257-11.
51. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. 2012. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. U. S. A. 109:1080-1085. http://dx.doi.org/10.1073/pnas.1112648109.
52. Corradin G, Céspedes N, Verdini A, Kajava AV, Arévalo-Herrera M, Herrera S. 2012. Malaria vaccine development using synthetic peptides as a technical platform. Adv. Immunol. 114:107-149. http://dx.doi.org/10.1016/B978-0-12-396548-6.00005-6.
53. Gordon DM, Cosgriff TM, Schneider I, Wasserman GF, Majarian WR, Hollingdale MR, Chulay JD. 1990. Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine. Am. J. Trop. Med. Hyg. 42:527-531.
54. Herrington DA, Nardin EH, Losonsky G, Bathurst IC, Barr PJ, Hollingdale MR, Edelman R, Levine MM. 1991. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Am. J. Trop. Med. Hyg. 45:695-701.
55. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR, Step Study Protocol Team. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905. http://dx.doi.org/10.1016/S0140-6736(08)61592-5.
56. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ, National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. 2011. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J. Immunol. 187:3391-3401. http://dx.doi.org/10.4049 /jimmunol.1101421.
57. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP, Huang Y, Spies GA, De Rosa SC, McElrath MJ. 2012. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J. Clin. Invest. 122:359-367. http://dx.doi.org/10.1172/JCI60202.
58. Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, Price DA, Gostick E, Gordon IJ, Ambrozak DR, Nason MC, Roederer M, Andrews CA, Maldarelli FM, Wiegand A, Kearney MF, Persaud D, Ziemniak C, Gottardo R, Ledgerwood JE, Graham BS, Koup RA, VRC 101 Study Team. 2013. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207:1829-1840. http://dx.doi.org/10.1093/infdis/jit098.